neointimal hyperplasia


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia.

neointimal hyperplasia

An increase in the thickness of the lining of a blood vessel in response to injury or vascular reconstruction. It is an important cause of vein graft obstruction after coronary artery bypass surgery and in the premature closure of other vascular conduits, e.g., in dialysis access devices. It is characterized by the migration of smooth muscle cells into the graft, followed by the release of cytokines that damage the vessel wall and contribute to its degradation by inflammation.
See also: hyperplasia
References in periodicals archive ?
EPCs derived from human early fetal aortas could be successfully transplanted into injured vessels and may inhibit neointimal hyperplasia after vascular injury.
RESORB study found that the degree of neointimal hyperplasia was similar to that of BMS.
Long-term outcomes of neointimal hyperplasia without neoatherosclerosis after drug-eluting stent implantation.
Morphometric examination of the anastomosed arteries from the PBS group showed different degrees of neointimal hyperplasia.
The long-term benefits of vascular reconstructive procedures, such as surgical arterial bypass, endarterectomy or balloon angioplasty, are significantly limited by restenosis secondary to neointimal hyperplasia (1, 2).
Neointimal hyperplasia in histological sections with adventitial VV neovascularization assessed using cross-sectional micro-CT images demonstrated a positive correlation between I/M ratio and the number of VV in the angioplasty group ( R [sup]2 = 0.
Elixir Medical's Novolimus Eluting Coronary Stent system was effective in reducing lumen loss and neointimal hyperplasia at four-month angiographic follow-up in patients treated with the device.
on their discovery of the role of the intracellular protein R-Ras in neointimal hyperplasia, angiogenesis and vascular proliferation.
Suppression of neointimal hyperplasia, the underlying cause of in-stent restenosis, by 17(beta)-estradiol released from the stent surface, represents a novel approach for drug eluting stents and is the basis for the ETHOS I and ETHOS II clinical studies.
Furthermore, PhotoPoint PDT inhibits neointimal hyperplasia after angioplasty in porcine coronary arteries and may also be a potential therapy for the prevention and treatment of clinical restenosis.
Results showed a statistically significant reduction in neointimal hyperplasia (cell overgrowth) in PhotoPoint treated arteries versus controls, with all treated arteries remaining patent at follow-up.